Short answer
ANI PHARMACEUTICALS INC (ANIP) filed an 8-K current report with the SEC on August 24, 2026 reporting Item 5.02 (Departure/Election of Directors or Officers). Henry Gosebruch appointed director through 2027 annual meeting, adding M&A, strategy, and biopharma leadership experience.
ANI PHARMACEUTICALS INC 8-K event analysis
AI summary of each reported item and its exhibits
Item 5.02 · Departure/Election of Directors or Officers
- Henry Gosebruch appointed director through 2027 annual meeting, adding M&A, strategy, and biopharma leadership experience
- Initial restricted stock award valued at $525,000, vesting in three equal annual installments
- Samy Shanmugam resigned as director effective immediately but remains Head of R&D and COO of New Jersey Operations
- Board transition separates Shanmugam’s governance role from ongoing operational responsibilities
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other ANI PHARMACEUTICALS INC 8-K filings
Get the next ANIP 8-K as it lands
Follow ANIP for push alerts, or ask the research agent what this filing means.